MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ
19.40
-0.56
-2.78%
After Hours: 19.46 +0.06 +0.31% 19:57 05/11 EDT
OPEN
19.99
PREV CLOSE
19.96
HIGH
20.99
LOW
19.27
VOLUME
3.07M
TURNOVER
--
52 WEEK HIGH
44.14
52 WEEK LOW
10.42
MARKET CAP
2.05B
P/E (TTM)
178.64
1D
5D
1M
3M
1Y
5Y
1D
Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026
TipRanks · 23h ago
Weekly Report: what happened at SRPT last week (0504-0508)?
Weekly Report · 1d ago
Sarepta Broadens Beyond Elevidys With siRNA Progress And FDA Milestones
Simply Wall St · 2d ago
Is Sarepta Therapeutics (SRPT) A Potential Opportunity After Sharp Multi‑Year Share Price Declines?
Simply Wall St · 3d ago
Trump plans to fire FDA commissioner Marty Makary, WSJ reports
TipRanks · 3d ago
Sarepta Therapeutics (SRPT) Gets a Buy from Wedbush
TipRanks · 3d ago
A Look At Sarepta Therapeutics (SRPT) Valuation After Its First Quarter Profit Turnaround
Simply Wall St · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise
Reuters · 4d ago
More
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.

Webull offers Sarepta Therapeutics Inc stock information, including NASDAQ: SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.